血清Hcy、HMGB1水平与多发性骨髓瘤患者预后的关系

doi:10.3969/j.issn.1671-7171.2023.02.004

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1173 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the relationship of serum homocysteine (Hcy) and high mobility group protein B1 (HMGB1) levels with the prognosis of patients with multiple myeloma (MM). 【Methods】A total of 72 MM patients treated in our hospital were divided into the good prognosis group (n=49) and the poor prognosis group (n=23) according to the survival of 3 years follow-up. The age,sex,body mass index (BMI),course of disease,smoking history,drinking history,hypertension history,anemia,light chain type,ISS staging data and the levels of bone marrow plasma cells,hemoglobin (Hb),blood calcium (Ca),blood creatinine (Scr),Hcy,and HMGB1 were compared between the two groups at admission. The predictive value of Hcy and HMGB1 levels on the poor prognosis of MM patients was analyzed with ROC curve,and the risk factors of the poor prognosis were identified with Logistic analysis. 【Results】The proportion of patients aged ≥ 60 years and the levels of Hcy and HMGB1 in the poor prognosis group were significantly higher than those in the good prognosis group (P<0.05). The area under the ROC curve predicted by Hcy and HMGB1 for the poor prognosis of MM patients was 0.815 and 0.777,respectively,(both P<0.05). Multivariate logistic regression analysis confirmed that age ≥ 60 years,Hcy ≥ 13.562 μmol/L and HMGB1 ≥ 216.919 pg/mL were risk factors for poor prognosis of MM patients (all P<0.05). 【Conclusion】The poor prognosis of MM patients is closely related to age,Hcy level and HMGB1 level,which deserves clinical attention.

Key words： Multiple Myeloma Cysteine/BL HMGB1 Protein/BL Prognosis

Received: 18 July 2022

PACS:

R733.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GU Min
	QIN Yun
	BAI Sha-sha
	et al

Cite this article:

GU Min,QIN Yun,BAI Sha-sha, et al. Relationship of Serum Hcy and HMGB1 with Prognosis of Patients with Multiple Myeloma[J]. JOURNAL OF CLINICAL RESEARCH, 2023, 40(2): 173-175.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2023.02.004 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2023/V40/I2/173

[1] ORLOWSKI R Z,MOREAU P,NIESVIZKY R,et al.Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma:updated overall survival,safety,and subgroups[J].Blood,2019,114(8):522.
[2] CHANG Z Y,THAMBOO T P,CHOONG C S,et al.Multiple myeloma-associated light chain amyloidosis and a proposed approach to monoclonal immunoglobulin-associated renal disease[J].Case Rep Nephrol Dialysis,2020,10(3):95-103.
[3] 董炎红,慕珂珂,李琰,等.血清同型半胱氨酸与高血压病不同中医证型的相关性研究[J].陕西中医,2019,40(4):453-455.
[4] CARR D F,WANG C W,BELLÓN T,et al.Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis[J].Br J Dermatol,2019,181(1):166-174.
[5] 张之南,沈悌.血液病诊断及疗效标准[M].第3版.北京:科学出版社,2007:232-234.
[6] HANG Q G,GONG W Y,WU H Y,et al.ZDKK1 suppresses WWP2 to enhance bortezomib resistance in multiple myeloma via regulating GLI2 ubiquitination.[J].Carcinogenesis,2021,42(10):1223-1231.
[7] 贺冠强,郭敏,索晓慧,等.HMGB1、维生素D₃水平与多发性骨髓瘤的相关性[J].中国现代医学杂志,2020,30(6):80-84.
[8] WANG B S,DUAN J J,ZHOU L,et al.The paradoxical pharmacological mechanisms of lenalidomide and bortezomib in the treatment of multiple myeloma.[J].Anticancer Drugs,2021,32(3):227-232.
[9] 张新芸,华冰清,高山,等.多发性骨髓瘤化疗医院感染风险预测模型的建立及应用价值[J].中华医院感染学杂志,2021,31(9):1396-1400.
[10] 郝苗,毛志刚,罗开宏,等.血清骨特异性碱性磷酸酶、同型半胱氨酸、护骨素变化对多发性骨髓瘤患者的临床应用价值[J].标记免疫分析与临床,2020,27(1):32-36.
[11] 郭改玲,张月玲,贾新勇,等.不同临床分期多发性骨髓瘤患者血清Hcy、sICAM-1、HMGB1水平变化及临床意义[J].实验与检验医学,2021,39(4):908-910.
[12] 郭治华,王煜,刘强,等.血清高迁移率族蛋白B1水平和血小板平均体积在急性胰腺炎患者病情评估及预后判断中的价值[J].中国医药,2020,15(10):1585-1589.
[13] 伏媛,魏小芳,冯友繁,等.血清同型半胱氨酸水平对初诊多发性骨髓瘤患者预后的影响及相关因素分析[J].中国实验血液学杂志,2021,29(2):530-534.